دورية أكاديمية
أعرض في EDS

Reirradiation for Recurrent Nasopharyngeal Carcinomas: Experience From an Academic Tertiary Center in a Low- to Middle-Income Country.

التفاصيل البيبلوغرافية
العنوان: Reirradiation for Recurrent Nasopharyngeal Carcinomas: Experience From an Academic Tertiary Center in a Low- to Middle-Income Country.
المؤلفون: Agas RAF; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Yu KKL; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Sogono PG; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Co LBA; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Jacinto JCKM; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Bacorro WR; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines., Mejia MBA; Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines.
المصدر: Journal of global oncology [J Glob Oncol] 2019 Feb; Vol. 5, pp. 1-14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101674751 Publication Model: Print Cited Medium: Internet ISSN: 2378-9506 (Electronic) Linking ISSN: 23789506 NLM ISO Abbreviation: J Glob Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2015]-[2019]
مواضيع طبية MeSH: Nasopharyngeal Carcinoma/*radiotherapy , Nasopharyngeal Neoplasms/*radiotherapy , Neoplasm Recurrence, Local/*radiotherapy , Re-Irradiation/*adverse effects , Re-Irradiation/*methods, Adult ; Aged ; Aged, 80 and over ; Dose Fractionation, Radiation ; Female ; Humans ; Male ; Middle Aged ; Radiosurgery ; Radiotherapy, Conformal ; Radiotherapy, Intensity-Modulated ; Retrospective Studies ; Salvage Therapy ; Survival Analysis ; Tertiary Care Centers ; Treatment Outcome ; Young Adult
مستخلص: Purpose: The objectives of this study were to report the oncologic outcomes and the treatment-related toxicities after reirradiation (re-RT) for recurrent nasopharyngeal carcinoma (rNPC) at our institution and to apply a recently published prognostic model for survival in rNPC in our cohort.
Patients and Methods: Thirty-two patients with rNPC treated at the authors' institution with re-RT were retrospectively reviewed. Treatment modalities for re-RT were intensity-modulated radiotherapy (n = 14), three-dimensional conformal radiotherapy (n = 9), single-fraction stereotactic radiosurgery (n = 6), fractionated stereotactic radiotherapy (n = 2), and high dose rate intracavitary brachytherapy (n = 1). Twenty-seven patients received re-RT with curative intent, whereas five patients were treated palliatively.
Results: Median follow-up time was 15.5 months (range, 1 to 123 months) for the entire cohort and 20 months (range, 3 to 123 months) for patients treated with curative intent. For the entire cohort, median locoregional recurrence-free survival (LRRFS) was 14 months, with actuarial 1- and 2-year LRRFS estimates of 67.5% and 44.0%, respectively. Median overall survival (OS) time was 38 months, with actuarial 1- and 2-year estimates of 74.2% and 57.2%, respectively. For patients treated with curative intent, median LRRFS was not reached. Actuarial 1- and 2-year LRRFS estimates were 68.2% and 54.5%, respectively. Median OS time after curative intent re-RT was 42 months, with actuarial 1- and 2-year estimates of 75.4% and 63.8%, respectively. One- and 2-year OS estimates based on risk stratification were 68.6% for high risk compared with 80.8% for low risk and 34.3% for high risk compared with 70.7% for low risk, respectively ( P = .223). Three patients (9.4%) developed symptomatic temporal lobe necrosis. There was no reported grade 5 treatment-related toxicity.
Conclusion: Results of the study suggest that re-RT is an effective and safe salvage treatment strategy for rNPC. Re-RT to a maximum equivalent dose in 2-Gy fractions of 60 Gy may yield good LRRFS and translate to prolonged OS.
References: Indian J Palliat Care. 2013 May;19(2):93-8. (PMID: 24049349)
Chin J Cancer. 2016 Feb 15;35:20. (PMID: 26879049)
J Clin Oncol. 2018 Mar 20;36(9):891-899. (PMID: 29412781)
Asian Pac J Cancer Prev. 2014 Jan;14(11):6513-8. (PMID: 24377559)
Radiology. 2015 Mar;274(3):752-63. (PMID: 25380454)
Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1117-26. (PMID: 10725621)
Jpn J Clin Oncol. 2010 Jul;40(7):603-12. (PMID: 20385654)
Am J Clin Oncol. 2005 Oct;28(5):464-71. (PMID: 16199985)
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):7-10. (PMID: 26700696)
Strahlenther Onkol. 2012 Aug;188(8):671-6. (PMID: 22580623)
Radiother Oncol. 2005 Nov;77(2):137-42. (PMID: 16260054)
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):676-83. (PMID: 22024207)
Clin Oncol (R Coll Radiol). 2012 Oct;24(8):569-76. (PMID: 22209574)
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6. (PMID: 7713792)
Radiat Oncol. 2011 May 24;6:54. (PMID: 21609453)
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):261-9. (PMID: 25066214)
Onco Targets Ther. 2017 Nov 27;10:5677-5683. (PMID: 29225474)
Oral Oncol. 2014 May;50(5):506-12. (PMID: 24529762)
Radiat Oncol. 2016 Jul 26;11(1):95. (PMID: 27460585)
PLoS One. 2016 Jan 12;11(1):e0146771. (PMID: 26757277)
Head Neck Oncol. 2009 May 23;1:13. (PMID: 19463191)
Chin Clin Oncol. 2016 Apr;5(2):26. (PMID: 27121886)
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):408-417. (PMID: 29100787)
Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):897-913. (PMID: 9531376)
Radiother Oncol. 1997 Oct;45(1):95-8. (PMID: 9364638)
Indian J Palliat Care. 2009 Jul;15(2):137-40. (PMID: 20668593)
Radiother Oncol. 2014 Jun;111(3):382-7. (PMID: 24993329)
Radiat Oncol J. 2017 Mar;35(1):1-15. (PMID: 28395502)
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8. (PMID: 20643517)
Radiat Oncol. 2014 Feb 19;9:60. (PMID: 24552293)
Radiother Oncol. 2007 Dec;85(3):456-62. (PMID: 18036689)
Sci Rep. 2017 Apr 7;7(1):721. (PMID: 28389658)
Chin J Cancer. 2014 Mar;33(3):159-64. (PMID: 23958058)
Ann Otol Rhinol Laryngol. 2017 Dec;126(12):789-797. (PMID: 29025277)
Acta Oncol. 2007;46(6):828-33. (PMID: 17653907)
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):459-64. (PMID: 8436524)
Sci Rep. 2016 Sep 12;6:32883. (PMID: 27616024)
Radiother Oncol. 2017 Jul;124(1):139-146. (PMID: 28433411)
J Cancer. 2017 Jul 5;8(11):2104-2113. (PMID: 28819412)
Head Neck. 2016 Apr;38 Suppl 1:E1102-9. (PMID: 26451876)
Chin J Cancer. 2016 Jun 29;35(1):59. (PMID: 27357728)
BMC Cancer. 2016 Oct 7;16(1):774. (PMID: 27717335)
Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Jun;132(3):147-51. (PMID: 25553970)
Radiat Oncol. 2011 Mar 01;6:22. (PMID: 21356126)
Eur J Cancer. 2012 Dec;48(18):3422-8. (PMID: 22835782)
تواريخ الأحداث: Date Created: 20190209 Date Completed: 20200623 Latest Revision: 20200623
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6426519
DOI: 10.1200/JGO.18.00191
PMID: 30735433
قاعدة البيانات: MEDLINE
الوصف
تدمد:2378-9506
DOI:10.1200/JGO.18.00191